# **PRODUCT** INFORMATION



**FLT3** Inhibitor

Item No. 18462

CAS Registry No.:	301305-73-7	<
Formal Name:	2-[(3,4-dimethoxybenzoyl)amino]-	<u>`</u> o
	4,5,6,7-tetrahydro-benzo[b]thiophene-3-	
	carboxamide	
Synonyms:	Fms-like Tyrosine Kinase Inhibitor, TCS 359	
MF:	C <sub>18</sub> H <sub>20</sub> N <sub>2</sub> O <sub>4</sub> S	0
FW:	360.4	
Purity:	≥98%	∧ <sup>S</sup> → <sup>N</sup> H
UV/Vis.:	λ <sub>max</sub> : 220, 256, 349 nm	
Supplied as:	A crystalline solid	NH <sub>2</sub>
Storage:	-20°C	
Stability:	≥4 years	<u> </u>

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

# Laboratory Procedures

FLT3 Inhibitor is supplied as a crystalline solid. A stock solution may be made by dissolving the FLT3 inhibitor in the solvent of choice, which should be purged with an inert gas. FLT3 Inhibitor is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of FLT3 inhibitor in these solvents is approximately 3 and 5 mg/ml, respectively.

FLT3 Inhibitor is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, FLT3 inhibitor should first be dissolved in DMF and then diluted with the aqueous buffer of choice. FLT3 inhibitor has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

# Description

Fms-like tyrosine kinase (FLT3) is a cell-surface receptor with important roles in stem cell development, hematopoiesis, and cancer.<sup>1,2</sup> FLT3 Inhibitor is a cell-permeable, ATP-competitive inhibitor of FLT3 (IC<sub>50</sub> = 27 nM) that blocks the proliferation of myelomonocytic leukemia MV4-11 cells (IC<sub>50</sub> = 0.41  $\mu$ M).<sup>3</sup> It is selective for FLT3 over a panel of 22 other kinases. FLT3 Inhibitor synergistically increases the cytotoxicity of an AF4-mimetic peptide against MV4-11 cells.<sup>4</sup>

# References

- 1. Grafone, T., Palmisano, M., Nicci, C., et al. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: Biology and treatment. Oncol. Rev. 6(1), 64-74 (2012).
- 2. Lyman, S.D. and Jacobsen, S.E.W. c-Kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood 91(4), 1101-1134 (1998).
- 3. Patch, R.J., Baumann, C.A., Liu, J., et al. Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3. Bioorg. Med. Chem. Lett. 16(12), 3282-3286 (2006).
- 4. Bennett, C.A., Winters, A.C., Barretti, N.N., et al. Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents. Leuk. Res. 33(7), 937-947 (2009).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

## SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

# WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/22/2022

# CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM